Affymax (AFFY) Continues Ripping on New OMONTYS Sourcing Agreement
Tweet
Share
E-mailGet Alerts AFFY Hot Sheet
Join SI Premium – FREE
Affymax, Inc. (Nasdaq: AFFY) is making a run for the second session Friday, following news on Thursday that partner Takeda Pharmaceuticals entered a supply agreement with for sourcing and supply of OMONTYS (peginesatide) Injection to Fresenius Medical Care North America and certain of its affiliates.
Shares are now up 37 percent over two days and 14.5 percent on Friday.
Shares are now up 37 percent over two days and 14.5 percent on Friday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA: issues early alert on Abiomed heart pump controller purge cassette issue
- Revolution Medicines prices RASONQUE at $39,800 per month
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Create E-mail Alert Related Categories
FDA, Insiders' Blog, Momentum MoversSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
